New radioactive drug targets Hard-to-Treat liver cancer
NCT ID NCT06852820
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests a radioactive drug called 177Lu-PSMA-617 in 10 patients with PSMA-positive liver cancer that has spread. The goal is to see if the drug is safe and can shrink tumors. Patients must have already tried one prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PSMA-617 (a radioactive drug)
What this could lead to
If successful, this could point toward a new treatment option for patients with PSMA-positive liver cancer that has spread.
What could go wrong
This is a very small pilot study (10 people) in early Phase 2, so results may not apply broadly. The drug is radioactive and may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••